Famous Patents
British merchant Peter Durand invented the tin can in 1810.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8182818 | Methods of using anti-TNF antibodies for treating radiation damage to the digestive tract In accordance with the invention, the development and use of antibodies within the digestive tract is provided. Antibodies are described that are used to treat disorders associated with altered permeability of the digestive tract. Antibodies are described with incre... | 05/22/2012 |
| 8158128 | Monoclonal antibodies to progastrin The present invention provides progastrin-binding molecules specific for progastrin that do not bind gastrin-17(G17), gastrin-34(G34), glycine-extended gastrin-17(G17-Gly), or glycine-extended gastrin-34(G34-Gly). Further, the invention provides monoclonal antibodie... | 04/17/2012 |
| 8133490 | Method and system to remove cytokine inhibitors in patients A method to treat cancer uses ultrapheresis, refined to remove compounds of less than 120,000 daltons molecular weight, followed by administration of replacement fluid, to stimulate the patient's immune system to attack solid tumors. In the preferred embodiment, the... | 03/13/2012 |
| 8128934 | Method for treatment or prevention of disease associated with functional disorder of regulatory T cell The inventors examined the role of MK in experimental autoimmune encephalomyelitis, which is a human model for multiple sclerosis. As a result, they discovered that MK has the effect of inhibiting regulatory T cells, and that the autoimmune mechanism induced by type... | 03/06/2012 |
| 8110195 | Antibody composition exhibiting cellular cytotoxicity due to glycosylation and containing ganglioside GM2 binding antibody The present invention relates to a cell for the production of an antibody molecule such as an antibody binding to ganglioside GM2, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody co... | 02/07/2012 |
| 8101184 | Treatment methods using Dkk-1 antibodies The present invention provides antibodies and immunologically functional fragments thereof that specifically bind Dkk-1 polypeptides. The subject antibodies and fragments bind with high affinity to a conformational epitope located in the carboxy region of the Dkk-1 ... | 01/24/2012 |
| 8101185 | Anti-il-5 antibody composition exhibiting cellular cytotoxicity due to glycosylation The present invention relates to a cell for the production of an anti-IL-5 antibody molecule having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method f... | 01/24/2012 |
| 8088384 | Anti-NGF antibodies and methods using same The invention concerns anti-NGF antibodies (such as anti-NGF antagonist antibodies), and polynucleotides encoding the same. The invention further concerns use of such antibodies and/or polynucleotides in the treatment and/or prevention of pain, including post-surgic... | 01/03/2012 |
| 8075893 | Pharmaceutical composition of F(ab′)antibody fragments and a process for the preparation thereof The present invention is directed to a pharmaceutical composition comprising F(ab′)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically ... | 12/13/2011 |
| 8062640 | High affinity human antibodies to PCSK9 An human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human proprotein convertase subtilisin/kexin type 9 (hPCSK9) characterized by the ability to reduce serum LDL cholesterol by 40-80% over a 24, 60 or 90 day period ... | 11/22/2011 |
| 8048422 | Tweak binding antibodies Anti-Tweak antibodies are described. ... | 11/01/2011 |
| 8043620 | Wise binding agents and epitopes The present invention relates to binding agents for WISE, and includes for their manufacture and use. ... | 10/25/2011 |
| 8043619 | Methods and uses of leptin in immune modulation The present invention describes the use of leptin for the immune modulation of the Th1/Th2 response. One aspect of the invention provides for a shift in the Th1/Th2 cell balance towards pro-inflammatory cytokine producing cells. This shift results from an increase i... | 10/25/2011 |
| 8034347 | Method for inhibiting apoptosis through the p75 neurotrophin receptor The present invention provides an isolated protein comprising a pro-domain of a proneurotrophin, methods for producing the protein, and pharmaceutical compositions containing the isolated protein. The invention also provides a nucleic acid molecule which encodes the... | 10/11/2011 |
| 7901686 | Hedgehog antibodies The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by embryonic patterning centers, and are involved in the formation of ordered spatial arrang... | 03/08/2011 |
| 7837999 | Method of increasing muscle mass with IGF-1 fusion polypeptides A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, ... | 11/23/2010 |
| 7785596 | Methods for enhancing survival and/or proliferation of neural stem cells and neurite extension enhancers therefor pharmaceutical compositions containing neural stem cells assay methods and screening methods Methods for enhancing survival and/or proliferation of neural stem cells and pharmaceutical compositions containing neural stem cells prepared by such methods, together with methods for assaying factors enhancing survival and/or proliferation of neural stem cells an... | 08/31/2010 |
| 7771724 | Modulation of platelet adhesion based on the surface-exposed beta-switch loop of platelet glycoprotein IB-alpha The invention relates to the adhesion of platelet GpIbα to strand β3 of domain A1 of von Willebrand factor (vWF), the strand β3 comprising amino acid residues at amino acid position 560-566 and/or a functional part or equivalent thereof, the platelet GpIbα, the ... | 08/10/2010 |
| 7722875 | Antibodies that bind canine pancreatic lipase Isolated nucleic acid molecules having a nucleotide sequence encoding canine pancreatic lipase polypeptides, allelic variants and fragments thereof. Vectors and host cells containing the polynucleotide sequences and methods for expressing the polypeptides. Monoclona... | 05/25/2010 |
| 7662385 | Agent for inhibiting proliferation of neural stem cells The object of the present invention is to provide methods for inhibiting proliferation of neural stem cells, an agent for inhibiting proliferation of neural stem cells, and methods for using the same. According to the method of the present invention, a galectin-1 in... | 02/16/2010 |
| 7632503 | Method of treating a muscle-related condition with modified IGF1 polypeptides A targeting fusion protein comprising a component that comprises a (i) ligand or derivative or fragment thereof that binds a pre-selected target surface protein, such as a receptor, and (ii) an active agent or therapeutic agent(s), and further optionally (iii) a mul... | 12/15/2009 |
| 7524502 | Modified anti-TNF alpha antibody The invention relates to the modification of antibodies reactive to human tumor necrosis factor alpha (TNF alpha) to result in anti-TNF alpha antibodies that are substantially non-immunogenic or less immunogenic than any non-modified parental antibody when used in v... | 04/28/2009 |
| 7504106 | Method and composition for treatment of renal failure with antibodies and their equivalents as partial or complete replacement for dialysis A method for treating patients with renal failure includes administering to them an effective amount of antibody or of a functional equivalent thereof to at least two of urea, creatinine, tumor necrosis factor alpha, interferon gamma, interleukin 6 and interleukin 1... | 03/17/2009 |
| 7494652 | Treatment of sepsis Compositions and methods are described for treatment of sepsis in animals, including humans. Unique and specific combinations of polyclonal antibodies directed to cytokines are shown to have a beneficial effect in animal models predictive of human therapy. ... | 02/24/2009 |
| 7485303 | Pharmaceutical composition of F(ab')2 antibody fragments The present invention is directed to a pharmaceutical composition comprising F(ab′)2 antibody fragments that are preferably free from albumin and of whole antibodies and also substantially free of pyrogens, and an effective amount of a pharmaceutically ... | 02/03/2009 |
| 7455839 | Method of inhibiting the formation of inhibin/betaglycan complexes with an anti-betaglycan antibody Inhibins and activins are protein hormones that reciprocally modulate a diversity of regulatory pathways. Competitive binding experiments revealed that betaglycan, the type III TGF-β receptor, also functions as an inhibin receptor. Betaglycan augments the binding o... | 11/25/2008 |
| 7439331 | Inhibition of complement activation The invention relates to factor D inhibitors, which bind to factor D and block the functional activity of factor D in complement activation. The inhibitors include antibody molecules, as well as homologues, analogues and modified or derived forms thereof, including ... | 10/21/2008 |
| 7435799 | TNF-α binding molecules The present invention relates to TNF-α binding molecules and nucleic acid sequences encoding TNF-α binding molecules. In particular, the present invention relates to TNF-α binding molecules with a high binding affinity, a high association rate, a low dissociation... | 10/14/2008 |
| 7427400 | Methods of cancer diagnosis and therapy targeted against a cancer stem line Improved methods for treatment of cancer which involve the targeting of slow-growing, relatively mutationally-spared cancer stem line are provided. These methods are an improvement over previous cancer therapeutic methods because they provide for very early cancer t... | 09/23/2008 |
| 7425330 | Methods of inhibiting TNFα activity in the blood of a patient Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 09/16/2008 |
| 7416729 | Methods of treating rheumatoid arthritis with anti-TNF antibodies Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 08/26/2008 |
| 7413865 | Diagnostic method for a transmissible spongiform encephalopathy or prion disease A method is provided for the diagnosis of a transmissible spongiform encephalopathy (TSE) or prion disease in an animal which comprises assaying a sample obtained from said animal to determine the number of hematopoietic cells of the erythroid, megakaryocyte or plat... | 08/19/2008 |
| 7410639 | Vascular endothelial growth factor D(VEGF-D) antibodies and methods of use VEGF-D, a new member of the PDGF family of growth factors, which among other things stimulates endothelial cell proliferation and angiogenesis and increases vascular permeability, as well as nucleotide sequences encoding it, methods for producing it, antibodies and ... | 08/12/2008 |
| 7404955 | Methods of inhibiting or neutralizing TNFα in patients with tissue injury Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-α (TNFα) and are useful in vivo diagnosis and therapy of a number of TNFα-mediated pathologies and conditions, as well as polynucleotides coding for murine and c... | 07/29/2008 |
| 7402313 | Method for controlling preeclampsia and eclampsia A method of controlling preeclampsia includes the steps of providing a supply of digoxin immune Fab (ovine), calculating an appropriate dosage of the digoxin immune Fab (ovine) based on a patient's weight and using an assumed endogenous digitalis-like factor level, ... | 07/22/2008 |
| 7390491 | Agents comprising midkine or an inhibitor thereof as active ingredient Midkine (MK), which is a retinoic acid-inducible heparin-binding growth factor, enhances neutrophilic migration and exists in an inflammatory state at a high concentration. The midkine or its inhibitors can be used for treating neutrophilic functional disorders or i... | 06/24/2008 |
| 7384634 | Connective tissue growth factor The present invention provides a novel polypeptide, Connective Tissue Growth Factor (CTGF), polynucleotides encoding CTGF and polynucleotides regulating CTGF expression. The invention also provides agents that modulate CTGF and therapeutic methods for using the agen... | 06/10/2008 |
| 7371384 | Compositions and methods of using angiopoietin-like 4 protein antibody ANGPTL4 compositions and methods of using such compositions, and agonists or antagonists thereof, for the diagnosis and treatment of diseases or disorders are included, including methods to modulate cell proliferation, cell adhesion, and cell migration. ... | 05/13/2008 |
| 7371819 | Polypeptides of the IFNα-17 gene The present invention relates to new polynucleotides derived from the nucleotide sequence of the IFNα-17 gene comprising new SNPs, and new polypeptides derived from the natural wild-type IFNα-17 protein comprising at least one mutation caused by at least one SNP o... | 05/13/2008 |
| 7371377 | Antibodies to polypeptides homologous to VEGF and BMP1 The present invention involves the identification and preparation of vascular endothelial growth factor-E (VEGF-E). VEGF-E is a novel polypeptide related to vascular endothelial growth factor (VEGF) and bone morphogenetic protein 1. VEGF-E has homology to VEGF inclu... | 05/13/2008 |
